share_log

10-K: Annual report

10-K: Annual report

10-K：年度报表
美股sec公告 ·  04/16 17:31
Moomoo AI 已提取核心信息
Conduit Pharmaceuticals, a pharmaceutical company, reported a net loss of $0.5 million for the year ended December 31, 2023, compared to a net loss of $4.9 million in the previous year. The company also experienced an increase in cash used in operating activities, reporting $7.7 million in 2023, up from $2.3 million in 2022. Despite completing a merger and a private placement totaling $20.0 million, Conduit Pharmaceuticals ended the year with an accumulated deficit of $11.3 million and acknowledged substantial doubt about its ability to continue as a going concern. The company's future plans include seeking additional funding through equity or debt financings to support its business plan. Conduit Pharmaceuticals is subject to industry risks such as regulatory approvals and dependence on key products and customers. The company's financial statements have been prepared under the assumption that it will continue as a going concern, without adjustments that might be necessary if the company is unable to continue in operation.
Conduit Pharmaceuticals, a pharmaceutical company, reported a net loss of $0.5 million for the year ended December 31, 2023, compared to a net loss of $4.9 million in the previous year. The company also experienced an increase in cash used in operating activities, reporting $7.7 million in 2023, up from $2.3 million in 2022. Despite completing a merger and a private placement totaling $20.0 million, Conduit Pharmaceuticals ended the year with an accumulated deficit of $11.3 million and acknowledged substantial doubt about its ability to continue as a going concern. The company's future plans include seeking additional funding through equity or debt financings to support its business plan. Conduit Pharmaceuticals is subject to industry risks such as regulatory approvals and dependence on key products and customers. The company's financial statements have been prepared under the assumption that it will continue as a going concern, without adjustments that might be necessary if the company is unable to continue in operation.
制药公司Conduit Pharmicals报告称，截至2023年12月31日的年度净亏损为50万美元，而上一年的净亏损为490万美元。该公司用于经营活动的现金也有所增加，2023年为770万美元，高于2022年的230万美元。尽管完成了总额为2,000万美元的合并和私募配售，但Conduit Pharmicals在年底的累计赤字为1,130万美元，并承认对其继续经营的能力存在重大疑问。该公司的未来计划包括通过股权或债务融资寻求额外资金，以支持其业务计划。Conduit Pharmicals面临行业风险，例如监管部门的批准以及对关键产品和客户的依赖。该公司的财务报表是在假设将继续作为持续经营企业编制的，如果公司无法继续运营，则不进行必要的调整。
制药公司Conduit Pharmicals报告称，截至2023年12月31日的年度净亏损为50万美元，而上一年的净亏损为490万美元。该公司用于经营活动的现金也有所增加，2023年为770万美元，高于2022年的230万美元。尽管完成了总额为2,000万美元的合并和私募配售，但Conduit Pharmicals在年底的累计赤字为1,130万美元，并承认对其继续经营的能力存在重大疑问。该公司的未来计划包括通过股权或债务融资寻求额外资金，以支持其业务计划。Conduit Pharmicals面临行业风险，例如监管部门的批准以及对关键产品和客户的依赖。该公司的财务报表是在假设将继续作为持续经营企业编制的，如果公司无法继续运营，则不进行必要的调整。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

独立文件3

独立文件4

独立文件5

独立文件6

独立文件7

独立文件8

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息